A multitier virtual screening study of phytoconstituents as Myeloid Cell Leukemias 1 inhibitors

References

• Ahamed, M., Akhtar, M. J., Khan, M. A. M., & Alhadlaq, H. A. (2021). Co-exposure of Bi 2 O 3 nanoparticles and bezo [a] pyrene-enhanced in vitro cytotoxicity of mouse spermatogonia cells. Environmental Science and Pollution Research International, 28(14), 17109–17118. https://doi.org/10.1007/s11356-020-12128-6
   PubMed Web of Science ®Google Scholar
• Ahamed, M., Javed Akhtar, M., & Alhadlaq, H. A. (2022). Combined effect of single-walled carbon nanotubes and cadmium on human lung cancer cells. Environmental Science and Pollution Research International, 29(58), 87844–87857. https://doi.org/10.1007/s11356-022-21933-0
   PubMed Web of Science ®Google Scholar
• Bolomsky, A., Vogler, M., Köse, M. C., Heckman, C. A., Ehx, G., Ludwig, H., & Caers, J. (2020). MCL-1 inhibitors, fast-lane development of a new class of anticancer agents. Journal of Hematology & Oncology, 13(1), 1–19. https://doi.org/10.1186/s13045-020-01007-9
   PubMed Web of Science ®Google Scholar
• Caenepeel, S., Brown, S. P., Belmontes, B., Moody, G., Keegan, K. S., Chui, D., Whittington, D. A., Huang, X., Poppe, L., Cheng, A. C., Cardozo, M., Houze, J., Li, Y., Lucas, B., Paras, N. A., Wang, X., Taygerly, J. P., Vimolratana, M., Zancanella, M., … Hughes, P. E. (2018). AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapiesAMG 176 alone and combined in hematologic cancer models. Cancer Discovery, 8(12), 1582–1597. https://doi.org/10.1158/2159-8290.CD-18-0387
   PubMed Web of Science ®Google Scholar
• Chen, L., & Fletcher, S. (2017). Mcl-1 inhibitors: A patent review. Expert Opinion on Therapeutic Patents, 27(2), 163–178. https://doi.org/10.1080/13543776.2017.1249848
   PubMed Web of Science ®Google Scholar
• Clifton, M. C., Dranow, D. M., Leed, A., Fulroth, B., Fairman, J. W., Abendroth, J., Atkins, K. A., Wallace, E., Fan, D., Xu, G., Ni, Z. J., Daniels, D., Van Drie, J., Wei, G., Burgin, A. B., Golub, T. R., Hubbard, B. K., & Serrano-Wu, M. H. (2015). A maltose-binding protein fusion construct yields a robust crystallography platform for MCL1. PloS One, 10(4), e0125010. https://doi.org/10.1371/journal.pone.0125010
   PubMed Web of Science ®Google Scholar
• Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7(1), 1–13. https://doi.org/10.1038/srep42717
   PubMed Web of Science ®Google Scholar
• Devi, S., Kumar, V., Singh, S. K., Dubey, A. K., & Kim, J.-J. (2021). Flavonoids: Potential candidates for the treatment of neurodegenerative disorders. Biomedicines, 9(2), 99. https://doi.org/10.3390/biomedicines9020099
   PubMed Web of Science ®Google Scholar
• Fairchild, C. K., Floros, K., Jacob, S., Coon, C., Puchalapalli, M., Hu, B., Dozmorov, M., Koblinski, J., Smith, S., Domson, G., & Ebi, H. (2020). Evaluation of combined BCL-2/MCL-1 inhibition as a therapeutic approach for synovial sarcoma. American Society of Clinical Oncology, 38(15_suppl), e23561-e23561.
   Web of Science ®Google Scholar
• Feng, B., LaPerle, J. L., Chang, G., & Varma, M. V. S. (2010). Renal clearance in drug discovery and development: Molecular descriptors, drug transporters and disease state. Expert Opinion on Drug Metabolism & Toxicology, 6(8), 939–952. https://doi.org/10.1517/17425255.2010.482930
   PubMed Web of Science ®Google Scholar
• Friberg, A., Vigil, D., Zhao, B., Daniels, R. N., Burke, J. P., Garcia-Barrantes, P. M., Camper, D., Chauder, B. A., Lee, T., Olejniczak, E. T., & Fesik, S. W. (2013). discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design. Journal of Medicinal Chemistry, 56(1), 15–30. https://doi.org/10.1021/jm301448p
   PubMed Web of Science ®Google Scholar
• Gélinas, C., & White, E. (2005). BH3-only proteins in control: Specificity regulates MCL-1 and BAK-mediated apoptosis. Genes & Development, 19(11), 1263–1268. https://doi.org/10.1101/gad.1326205
   PubMed Web of Science ®Google Scholar
• Goel, B., Tripathi, N., Bhardwaj, N., Sahu, B., & Jain, S. K. (2021). Therapeutic potential of genus pongamia and derris: Phytochemical and bioactivity. Mini Reviews in Medicinal Chemistry, 21(8), 920–951. https://doi.org/10.2174/1389557520999201124211846
   PubMed Web of Science ®Google Scholar
• Huey, R., Morris, G. M., & Forli, S. (2012). Using AutoDock 4 and AutoDock vina with AutoDockTools: A tutorial. The Scripps Research Institute Molecular Graphics Laboratory, 10550, 92037.
   Google Scholar
• Ji, M., Li, J., Yu, H., Ma, D., Ye, J., Sun, X., & Ji, C. (2009). Simultaneous targeting of MCL1 and ABCB1 as a novel strategy to overcome drug resistance in human leukaemia. British Journal of Haematology, 145(5), 648–656. https://doi.org/10.1111/j.1365-2141.2009.07678.x
   PubMed Web of Science ®Google Scholar
• Kang, M. H., & Reynolds, C. P. (2009). Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 15(4), 1126–1132. https://doi.org/10.1158/1078-0432.CCR-08-0144
   PubMed Web of Science ®Google Scholar
• Kim, S., Thiessen, P. A., Bolton, E. E., Chen, J., Fu, G., Gindulyte, A., Han, L., He, J., He, S., Shoemaker, B. A., Wang, J., Yu, B., Zhang, J., & Bryant, S. H. (2016). PubChem substance and compound databases. Nucleic Acids Research, 44(D1), D1202–D1213. https://doi.org/10.1093/nar/gkv951
   PubMed Web of Science ®Google Scholar
• Kotschy, A., Szlavik, Z., Murray, J., Davidson, J., Maragno, A. L., Le Toumelin-Braizat, G., Chanrion, M., Kelly, G. L., Gong, J.-N., Moujalled, D. M., Bruno, A., Csekei, M., Paczal, A., Szabo, Z. B., Sipos, S., Radics, G., Proszenyak, A., Balint, B., Ondi, L., … Geneste, O. (2016). The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature, 538(7626), 477–482. https://doi.org/10.1038/nature19830
   PubMed Web of Science ®Google Scholar
• Lagunin, A., Stepanchikova, A., Filimonov, D., & Poroikov, V. (2000). PASS: Prediction of activity spectra for biologically active substances. Bioinformatics (Oxford, England), 16(8), 747–748. https://doi.org/10.1093/bioinformatics/16.8.747
   PubMed Web of Science ®Google Scholar
• Lee, E. F., Harris, T. J., Tran, S., Evangelista, M., Arulananda, S., John, T., Ramnac, C., Hobbs, C., Zhu, H., Gunasingh, G., Segal, D., Behren, A., Cebon, J., Dobrovic, A., Mariadason, J. M., Strasser, A., Rohrbeck, L., Haass, N. K., Herold, M. J., & Fairlie, W. D. (2019). BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death & Disease, 10(5), 342. https://doi.org/10.1038/s41419-019-1568-3
   PubMedGoogle Scholar
• Lipinski, C. A. (2004). Lead-and druglike compounds: The rule-of-five revolution. Drug Discovery Today. Technologies, 1(4), 337–341. https://doi.org/10.1016/j.ddtec.2004.11.007
   PubMedGoogle Scholar
• Mohanraj, K., Karthikeyan, B. S., Vivek-Ananth, R. P., Chand, R. P. B., Aparna, S. R., Mangalapandi, P., & Samal, A. (2018). IMPPAT: A curated database of Indian medicinal plants, phytochemistry and therapeutics. Scientific Reports, 8(1), 1–17. https://doi.org/10.1038/s41598-018-22631-z
   PubMed Web of Science ®Google Scholar
• Ou-Yang, S.-S., Lu, J.-Y., Kong, X.-Q., Liang, Z.-J., Luo, C., & Jiang, H. (2012). Computational drug discovery. Acta Pharmacologica Sinica, 33(9), 1131–1140. https://doi.org/10.1038/aps.2012.109
   PubMed Web of Science ®Google Scholar
• Owor, R. O., Derese, S., Bedane, K. G., Zühlke, S., Ndakala, A., & Spiteller, M. (2020). Isoflavones from the seedpods of Tephrosia vogelii and pyrazoisopongaflavone with anti-inflammatory effects. Fitoterapia, 146, 104695. https://doi.org/10.1016/j.fitote.2020.104695
   PubMed Web of Science ®Google Scholar
• Papaleo, E., Mereghetti, P., Fantucci, P., Grandori, R., & De Gioia, L. (2009). Free-energy landscape, principal component analysis, and structural clustering to identify representative conformations from molecular dynamics simulations: The myoglobin case. Journal of Molecular Graphics & Modelling, 27(8), 889–899. https://doi.org/10.1016/j.jmgm.2009.01.006
   PubMed Web of Science ®Google Scholar
• Pires, D. E., Blundell, T. L., & Ascher, D. B. (2015). pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. Journal of Medicinal Chemistry, 58(9), 4066–4072. https://doi.org/10.1021/acs.jmedchem.5b00104
   PubMed Web of Science ®Google Scholar
• Placzek, W. J., Wei, J., Kitada, S., Zhai, D., Reed, J. C., & Pellecchia, M. (2010). A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy. Cell Death & Disease, 1(5), e40. https://doi.org/10.1038/cddis.2010.18
   PubMedGoogle Scholar
• Quinn, B. A., Dash, R., Azab, B., Sarkar, S., Das, S. K., Kumar, S., Oyesanya, R. A., Dasgupta, S., Dent, P., Grant, S., Rahmani, M., Curiel, D. T., Dmitriev, I., Hedvat, M., Wei, J., Wu, B., Stebbins, J. L., Reed, J. C., Pellecchia, M., Sarkar, D., & Fisher, P. B. (2011). Targeting Mcl-1 for the therapy of cancer. Expert Opinion on Investigational Drugs, 20(10), 1397–1411. https://doi.org/10.1517/13543784.2011.609167
   PubMed Web of Science ®Google Scholar
• Richmond, T. J. (1984). Solvent accessible surface area and excluded volume in proteins: Analytical equations for overlapping spheres and implications for the hydrophobic effect. Journal of Molecular Biology, 178(1), 63–89. https://doi.org/10.1016/0022-2836(84)90231-6
   PubMed Web of Science ®Google Scholar
• Sliwoski, G., Kothiwale, S., Meiler, J., & Lowe, E. W. (2014). Computational methods in drug discovery. Pharmacological Reviews, 66(1), 334–395. https://doi.org/10.1124/pr.112.007336
   PubMed Web of Science ®Google Scholar
• Spencer, A., Rosenberg, A. S., Jakubowiak, A., Raje, N., Chatterjee, M., Trudel, S., Bahlis, N. J., Siegel, D. S., Wilop, S., Harrison, S. J., NagaKrishna, M., Dhuria, S., Hindoyan, A., McIver, Z., Henary, H., Morrow, P. K., & Roberts, A. (2019). A phase 1, first-in-human study of AMG 176, a selective MCL-1 inhibitor, in patients with relapsed or refractory multiple myeloma. Clinical Lymphoma Myeloma and Leukemia, 19(10), e53–e54. https://doi.org/10.1016/j.clml.2019.09.081
   PubMed Web of Science ®Google Scholar
• Stewart, M. L., Fire, E., Keating, A. E., & Walensky, L. D. (2010). The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nature Chemical Biology, 6(8), 595–601. https://doi.org/10.1038/nchembio.391
   PubMed Web of Science ®Google Scholar
• Thomas, L. W., Lam, C., & Edwards, S. W. (2010). Mcl-1; the molecular regulation of protein function. FEBS Letters, 584(14), 2981–2989. https://doi.org/10.1016/j.febslet.2010.05.061
   PubMed Web of Science ®Google Scholar
• Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455–461. https://doi.org/10.1002/jcc.21334
   PubMed Web of Science ®Google Scholar
• Van Der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A. E., & Berendsen, H. J. C. (2005). GROMACS: Fast, flexible, and free. Journal of Computational Chemistry, 26(16), 1701–1718. https://doi.org/10.1002/jcc.20291
   PubMed Web of Science ®Google Scholar
• Wang, H., Guo, M., Wei, H., & Chen, Y. (2021). Targeting MCL-1 in cancer: Current status and perspectives. Journal of Hematology & Oncology, 14(1), 1–18. https://doi.org/10.1186/s13045-021-01079-1
   PubMed Web of Science ®Google Scholar
• Wei, A. H., Roberts, A. W., Spencer, A., Rosenberg, A. S., Siegel, D., Walter, R. B., Caenepeel, S., Hughes, P., McIver, Z., Mezzi, K., Morrow, P. K., & Stein, A. (2020). Targeting MCL-1 in hematologic malignancies: Rationale and progress. Blood Reviews, 44, 100672. https://doi.org/10.1016/j.blre.2020.100672
   PubMed Web of Science ®Google Scholar
• Wu, Y., Tepper, H. L., & Voth, G. A. (2006). Flexible simple point-charge water model with improved liquid-state properties. The Journal of Chemical Physics, 124(2), 024503. https://doi.org/10.1063/1.2136877
   PubMed Web of Science ®Google Scholar
• Zhang, L., Ai, H., Chen, W., Yin, Z., Hu, H., Zhu, J., Zhao, J., Zhao, Q., & Liu, H. (2017). CarcinoPred-EL: Novel models for predicting the carcinogenicity of chemicals using molecular fingerprints and ensemble learning methods. Scientific Reports, 7(1), 2118. https://doi.org/10.1038/s41598-017-02365-0
   PubMed Web of Science ®Google Scholar